Cat-PAD
Sponsors
Circassia Limited, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
Cat AllergyCat HypersensitivityRhinoconjunctivitis
Phase 1
Safety of Cat-PAD in Cat Allergic Subjects
CompletedNCT00685711
Start: 2008-01-31End: 2008-07-31Updated: 2008-08-06
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis
CompletedNCT01383603
Start: 2011-10-31End: 2014-05-31Updated: 2014-06-11
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis
CompletedNCT01383590
Start: 2011-10-31End: 2013-12-31Updated: 2014-01-22
Phase 2
Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects
CompletedNCT00729508
Start: 2008-08-31End: 2009-05-31Target: 120Updated: 2009-07-08
Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma
CompletedNCT00867906
Start: 2009-03-31End: 2010-04-30Target: 48Updated: 2010-05-06
Cat-PAD Exposure Chamber Study
CompletedNCT01033344
Start: 2010-01-31End: 2010-09-30Target: 210Updated: 2010-10-01
Paediatric Safety Study in Cat-PAD
CompletedNCT01921257
Start: 2013-08-31End: 2015-12-31Updated: 2018-05-14
A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy
CompletedNCT02311413
Start: 2015-03-09End: 2018-07-18Updated: 2018-11-02